logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
BackJournal Details
B

Bulletin du Cancer

IF0.8
Papers144
Citations1421
Journal Papers 149
Publication Date
delete
Cardiovascular toxicities of major oral targeted therapies used in solid tumor
deleteBulletin du Cancer
IF0.8
delete2026-05-01
delete0
PREAI
deleteNannini, Simon; Droesch, Clement; Schultz, Emilie; Moinard-Butot, Fabien
deleteShare
deleteSave
Genetic effects of vascular endothelial growth factor A (VEGF-A) gene mutations and their association with poor clinical characteristics of prostate cancer
deleteBulletin du Cancer
IF0.8
delete2026-05-01
delete0
PREAI
deleteElghazali, Khaoula; Ennaji, Youssef; Laraqui, Abdelilah; Ennibi, Khalid; Ennaji, Moulay Mustapha
deleteShare
deleteSave
Rituximab maintenance in marginal zone lymphoma: Evidence from a real-world single center case series study
deleteBulletin du Cancer
IF0.8
delete2026-05-01
delete0
PREAI
deletePezzullo, Luca; Settembre, Lorenzo; D'Addona, Matteo; Gigantiello, Andrea; Guariglia, Roberto; Serio, Bianca; Mettivier, Laura; Malandrini, Antonella; Signorile, Giovanni; Giudice, Valentina; Selleri, Carmine
deleteShare
deleteSave
French recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2024-2025:Management of high-grade ovarian epithelial cancer (vol 113, pg 191, 2026)
deleteBulletin du Cancer
IF0.8
delete2026-05-01
delete0
PREAI
deleteSelle, Frederic; Rodrigues, Manuel; You, Benoit; Gladieff, Laurence; Hardy-Bessard, Anne-Claire; Rouge, Thibault de la Motte; Fumet, Jean-David; Le Saux, Olivia; Colombo, Pierre-Emmanuel; Ferron, Gabriel; Treilleux, Isabelle; Rouleau, Etienne; Falandry, Claire; Joly, Florence; Frenel, Jean-Sebastien; Quesada, Stanislas; Classe, Jean-Marc
deleteShare
deleteSave
Metabolic and cardiovascular disorders with lorlatinib: How to detect and manage them in practice?
deleteBulletin du Cancer
IF0.8
delete2026-05-01
delete0
PREAI
deleteArrondeau, Jennifer; Ederhy, Stephane; Heron, Christophe; Blanchet, Benoit; Avrillon, Virginie; Levenbruck, Chloe; Lena, Herve; Cortot, Alexis
deleteShare
deleteSave
Evaluation of the return-to-work rate in systemically treated non-small cell lung cancer patient
deleteBulletin du Cancer
IF0.8
delete2026-05-01
delete0
PREAI
deleteCap, Marie; Nael, Virginie; Mouezy, Loan; Fourage, Ludivine; Raimbourg, Judith; Hulo, Pauline; Chen, Jeanne; Bordenave, Stephanie; Corvaisier-Chiron, Murielle; Pons-Tostivint, Elvire
deleteShare
deleteSave
Real-life first-line systemic treatments for metastatic non-small cell lung cancer (mNSCLC)-Data from the KBP-2020-CPHG cohort
deleteBulletin du Cancer
IF0.8
delete2026-05-01
delete0
PREAI
deleteCorre, Romain; Lena, Herve; Eberlin, Adrien; Spampinato, Axelle; Guimard, Valerie; Dousa, Stephanie; Debieuvre, Didier
deleteShare
deleteSave
Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia
deleteBulletin du Cancer
IF0.8
delete2026-05-01
delete0
PREAI
deleteCoste, Arthur; Quinquenel, Anne
deleteShare
deleteSave
Cancer in ten years: Between major innovations, environmental factors and risks of inequity
deleteBulletin du Cancer
IF0.8
delete2026-05-01
delete1
PREAI
deleteDelfraissy, Jean-Francois
deleteShare
deleteSave
Which access in France to innovative treatments and testing for patients with cancer?
deleteBulletin du Cancer
IF0.8
delete2026-05-01
delete0
PREAI
deleteGalaup, Ariane; Izard, Faustina; Petit, Laurent; Lavie, Frederic
deleteShare
deleteSave
ScRNA-Seq: A way to reveal the potential mechanisms of metastasis in small cell lung cancer
deleteBulletin du Cancer
IF0.8
delete2026-05-01
delete0
PREAI
deleteGuan, Xi ling; Gan, Deng xue; Wu, Yong; Zhang, Ying
deleteShare
deleteSave
Summary of second-line treatment of stage IV NSCLC without oncogenic addiction
deleteBulletin du Cancer
IF0.8
delete2026-05-01
delete0
PREAI
deletePierret, Thomas; Descourt, Renaud; Corre, Romain; Tomasini, Pascale; Decroisette, Chantal
deleteShare
deleteSave
Antibody drug conjugates: Use and optimization in HER2-negative metastatic breast cancers (triple negative, RH+/HER2-)
deleteBulletin du Cancer
IF0.8
delete2026-05-01
delete0
PREAI
deleteSaghatchian, Mahasti; Ciccolini, Joseph; Loirat, Delphine
deleteShare
deleteSave
Toxicity of NTRK inhibitors: A clinical overview
deleteBulletin du Cancer
IF0.8
delete2026-05-01
delete0
PREAI
deleteCoppin, Robin; Lemelle, Lauriane; Orbach, Daniel
deleteShare
deleteSave
Geospatial assessment of accessibility and territorial equity in lung cancer screening: A regional study
deleteBulletin du Cancer
IF0.8
delete2026-05-01
delete0
PREAI
deleteSchein, Josephine; Besnier, Marc; Poupin, Elodie; Freche, Bernard
deleteShare
deleteSave
Sugemalimab as monotherapy for unresectable stage III non-small cell lung cancer with PD-L1 expression ≥ 1%, without oncogenic driver alterations and without progression after chemoradiation
deleteBulletin du Cancer
IF0.8
delete2026-05-01
delete0
PREAI
deleteNebbache, Rafik; Mogenet, Alice
deleteShare
deleteSave
Vimseltinib in non-resecable tenosynovial giant cell tumor
deleteBulletin du Cancer
IF0.8
delete2026-05-01
delete0
PREAI
deleteDe Smet, Mathieu; Toulmonde, Maud
deleteShare
deleteSave
Low-dose screening for bronchopulmonary cancer: A general practitioner's perspective
deleteBulletin du Cancer
IF0.8
delete2026-05-01
delete0
PREAI
deletePoupin, Elodie; Hays, Yohann; Freche, Gael; Freche, Bernard
deleteShare
deleteSave
CANCERIMMUNE: A new INCa network designed to strengthen expertise in cancers of immunocompromised patients
deleteBulletin du Cancer
IF0.8
delete2026-04-01
delete0
PREAI
deleteVeyri, Marianne; Spano, Jean-Philippe; Baron, Marine; Choquet, Sylvain; Abbar, Baptiste
deleteShare
deleteSave
Tislelizumab in the perioperative treatment of resecable non-small cells lung cancers at high risk of recurrence in combination with neoadjuvant chemotherapy
deleteBulletin du Cancer
IF0.8
delete2026-04-01
delete0
PREAI
deleteBelloir, Pierre; Messekher, Merouane
deleteShare
deleteSave